Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceSin categoríaVideos

EHA 2025 | Expert interviews

During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival and quality of life. Dr. Sundar Jagannath discusses the long-term remission and survival for relapsed/refractory patients after treatment with ciltacabtagene…

Read more

Join our EHA 2025 highlights webinar

To help patients and advocates digest the most important myeloma news from the European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, Myeloma Patients Europe (MPE) will host a webinar on Tuesday, 24 June at 17:00 CET. The session will be led by Dr. Ulf-Henrik Mellqvist, Haematologist and Associate Professor at…

Read more

Myeloma EHA 2025 preview

The European Hematology Association (EHA) 2025 Annual Congress, the largest haematology event in Europe, will take place from 12 – 15 June in Milan, Italy. The meeting will bring together experts from across the globe to present the latest advances in haematological diseases, including myeloma. Myeloma Patients Europe (MPE) will be attending the congress to…

Read more

EMA CHMP gives positive opinion on belantamab mafodotin combinations for relapsed/refractory myeloma patients

On the 23 May 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of two belantamab mafodotin combinations for the treatment of patients with relapsed and/or refractory myeloma. The first combination is with bortezomib (a proteasome inhibitor) plus the steroid dexamethasone (BVd) in patients who have received at least one prior therapy.…

Read more

European Commission approves linvoseltamab for the treatment of relapsed and refractory myeloma

On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when the results of other, larger clinical trials become available. This approval is based on the favourable recommendation issued by the…

Read more

EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients

On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…

Read more
August

September 2026

October
MO
TU
WE
TH
FR
SA
SU
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
Events for 1st September
No Events
Events for 2nd September
No Events
Events for 3rd September
No Events
Events for 4th September
No Events
Events for 5th September
No Events
Events for 6th September
No Events
Events for 7th September
No Events
Events for 8th September
No Events
Events for 9th September
No Events
Events for 10th September
No Events
Events for 11th September
No Events
Events for 12th September
No Events
Events for 13th September
No Events
Events for 14th September
No Events
Events for 15th September
No Events
Events for 16th September
No Events
Events for 17th September
No Events
Events for 18th September
No Events
Events for 19th September
No Events
Events for 20th September
No Events
Events for 21st September
No Events
Events for 22nd September
No Events
Events for 23rd September
No Events
Events for 24th September
No Events
Events for 25th September
No Events
Events for 26th September
No Events
Events for 27th September
No Events
Events for 28th September
No Events
Events for 29th September
No Events
Events for 30th September
No Events